TUBB and breast carcinoma: Taking into account the fact that the analysis revealed that TUBB mRNA might be used as a predictive biomarker of worse prognosis in ERα-positive breast cancer patients and better prognosis in ERα-negative breast cancer patients, and that breast cancer treatments such as vinblastine, vincristine, and vinorelbine target TUBB directly, these results suggest that clinicians should avoid using these drugs in ERα-negative breast cancer patients and use them only on ERα-positive breast cancer patients.